combination therapy with glp-1 receptor agonist and sglt2 inhibitor Combining Agonists Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Quadruple therapy (SGLT2i + GLP-1RA
Description
A fresh analysis of the clinical and financial implications of comprehensive coverage in Medicare of GLP-1s for all current FDA indications (type 2 diabetes, obesity, heart disease and metabolic-associated steatohepatitis) offers some hope for long-term cost savings
Yang J-L, Chen W-Y, Chen S-D
Wegovy is injected under the skin once a week
The LEAD (Liraglutide Effect and Action Diabetes) program reported that liraglutide significantly reduced weight and improved glycated haemoglobin (HbA1c) compared to placebo/standard of care [24,25,26,27,28,29,30,31]
